ConductScience.org, home

Paper11907488

Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).

Christensen M and 8 others. Clin Pharmacol Ther, 2002. Cited by 77 papers, by iCite.

Cite this record

ConductScience Library. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Papers, record 11907488. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/11907488

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).
PubMed
Journal
Clin Pharmacol Ther
PubMed
Year
2002
PubMed
Publication types
Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
77
iCite
Relative citation ratio, by iCite
2.64
iCite
Revised in PubMed
2026-01-28
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Christensen MMagnus
2Tybring GGunnel
3Mihara KKazuo
4Yasui-Furokori NNorio
5Carrillo JAJuan Antonio
6Ramos SISara I
7Andersson KKatarina
8Dahl MLMarja-Liisa
9Bertilsson LLeif

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Adrenergic AgentsMajor topic
CaffeineMajor topic
Central Nervous System StimulantsMajor topic
DebrisoquinMajor topic
Enzyme InhibitorsMajor topic
FluvoxamineMajor topic
OmeprazoleMajor topic
Selective Serotonin Reuptake InhibitorsMajor topic
Adult
Area Under Curve
Cytochrome P-450 CYP1A2 Inhibitors
Dose-Response Relationship, Drug
Drug Interactions
Female
Humans
Male
Middle Aged

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
1R01 GM60548-01A2NIGMS NIH HHSUnited StatesR01GM605480PubMedNIH RePORTER
R01GM060548NIHNIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT05216614Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 ParosmiaBackground

Source ClinicalTrials.gov

Download CSV of trials

Cited by30

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 77 citations.

PMIDTitleJournalYearIn PapersSource
42234077Collecting Metabolite Pharmacokinetics in Drug-Drug Interaction Studies: A Review of Industry Practices and Data Utilization.Clin Pharmacokinet2026https://conductscience.org/library/papers/42234077PubMed
41247448The Impact of Fluvoxamine on Clozapine and Norclozapine Serum Concentrations.Eur J Drug Metab Pharmacokinet2026https://conductscience.org/library/papers/41247448PubMed
39870954An Exploration of the Interplay Between Caffeine and Antidepressants Through the Lens of Pharmacokinetics and Pharmacodynamics.Eur J Drug Metab Pharmacokinet2025https://conductscience.org/library/papers/39870954PubMed
36946597Beyond "Psychotropic": Repurposing Psychiatric Drugs for COVID-19, Alzheimer's Disease, and Cancer.J Clin Psychiatry2023https://conductscience.org/library/papers/36946597PubMed
36760517Polymorphisms in the gene encoding CYP1A2 influence prostate cancer risk and progression.Oncol Lett2023https://conductscience.org/library/papers/36760517PubMed
36557319Optimising Fluvoxamine Maternal/Fetal Exposure during Gestation: A Pharmacokinetic Virtual Clinical Trials Study.Metabolites2022https://conductscience.org/library/papers/36557319PubMed
35280254Pharmacokinetics of Caffeine: A Systematic Analysis of Reported Data for Application in Metabolic Phenotyping and Liver Function Testing.Front Pharmacol2021https://conductscience.org/library/papers/35280254PubMed
33940506Disease-drug and drug-drug interaction in COVID-19: Risk and assessment.Biomed Pharmacother2021https://conductscience.org/library/papers/33940506PubMed
33363564How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?Front Genet2020https://conductscience.org/library/papers/33363564PubMed
33180097Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.JAMA2020https://conductscience.org/library/papers/33180097PubMed
29569723Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin.Clin Pharmacol Ther2018https://conductscience.org/library/papers/29569723PubMed
27437087Inhibition of Cytochrome P450 by Propolis in Human Liver Microsomes.Toxicol Res2016https://conductscience.org/library/papers/27437087PubMed
26936044Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers.Clin Pharmacokinet2016https://conductscience.org/library/papers/26936044PubMed
23023659Psychotropic drug-drug interactions involving P-glycoprotein.CNS Drugs2012https://conductscience.org/library/papers/23023659PubMed
20582584Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy.Eur J Clin Pharmacol2010https://conductscience.org/library/papers/20582584PubMed
19902987Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.Clin Pharmacokinet2009https://conductscience.org/library/papers/19902987PubMed
18224311Estimation of the area under the concentration-time curve of racemic lansoprazole by using limited plasma concentration of lansoprazole enantiomers.Eur J Clin Pharmacol2008https://conductscience.org/library/papers/18224311PubMed
17596106Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide.Clin Pharmacokinet2007https://conductscience.org/library/papers/17596106PubMed
17471183Tricyclic antidepressant pharmacology and therapeutic drug interactions updated.Br J Pharmacol2007https://conductscience.org/library/papers/17471183PubMed
16944962Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.Drug Saf2006https://conductscience.org/library/papers/16944962PubMed

See all 30 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CYP1A21544PubTator's text mininghttps://conductscience.org/library/genes/1544NCBI Gene
CYP2C191557PubTator's text mininghttps://conductscience.org/library/genes/1557NCBI Gene
CYP2D61565PubTator's text mininghttps://conductscience.org/library/genes/1565NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/11907488

GET https://conductscience.org/api/papers/v1/11907488/cited_by?page=2